Search results
Drugmaker AbbVie expects Humira volume erosion to worsen
Reuters via Yahoo News· 3 days ago(Reuters) -AbbVie expects a drop in sales volumes of its blockbuster arthritis drug Humira to deepen...
Earnings call: AbbVie surpasses Q1 expectations, announces CEO transition By Investing.com
Investing.com· 5 hours agoThe earnings call also marked a significant leadership transition, with CEO Rick Gonzalez announcing...
‘AI Craze’ Powers Best Week in 2024 for Stocks: Markets Wrap
Bloomberg via Yahoo Finance· 3 days ago(Bloomberg) -- A rally in the world’s largest technology companies lifted stocks, with Wall Street...
AbbVie tries to reassure investors on Humira biosimilar threat
BioPharma Dive via Yahoo Finance· 3 days agoAlthough that has meant Humira’s market share dropped from 96% to 81% over two weeks, Stewart said...
Psoriasis and Depression: What’s the Connection?
Verywell Health via Yahoo News· 10 hours agoPsoriasis is a chronic skin condition that can affect your mood, and many people with psoriasis experience depression. Here’s what you can do if you feel...
AbbVie Is 'Firing On All Cylinders,' But Its Stock Doesn't Show That
Investor's Business Daily· 3 days ago"This is despite the significant increase in U.S. biosimilar market share in April," Leerink...
Gear Up for AbbVie (ABBV) Q1 Earnings: Wall Street Estimates for Key Metrics
Zacks· 7 days agoFree Report) will announce quarterly earnings of $2.26 per share in its forthcoming report, representing a decline of 8.1% year over year. Ahead of a company's earnings disclosure, it is crucial ...
AbbVie Lifts 2024 Forecast as Newer Drugs Replace Humira Losses
Bloomberg· 3 days agoAbbVie Inc. lifted its full-year profit guidance as newer anti-inflammatory treatments like Rinvoq...
Better Dividend Stock: AbbVie or Johnson & Johnson?
Motley Fool via Yahoo Finance· 2 days agoEven so, AbbVie expects to return to top-line growth in 2025. Its roster of newer medicines is picking up the slack. That's particularly the case with ...
AbbVie Is 'Firing On All Cylinders,' But Its Stock Isn't
Investor's Business Daily· 3 days agoShares tumbled despite a first-quarter beat and earnings guidance increase.